Amarin (AMRN) vs Aquestive Therapeutics (AQST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amarin (AMRN) has outperformed Aquestive Therapeutics (AQST) over the past year, losing 35.5% versus a loss of 39.5%. Over five years, AQST leads with a -45.7% price change compared with -85.5% for AMRN. Amarin is the larger company by market cap ($444.4 million vs $434.9 million), about 1.0 times the size.
Amarin converts more of its revenue into profit, with a net margin of -18.2% versus -188.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | AQST |
|---|---|---|
| Share price | $10.57 | $3.46 |
| Market cap | $444.39M | $434.88M |
| 1-day change | -6.13% | -6.61% |
| YTD return | -24.28% | -46.44% |
| 1-year return | -35.47% | -39.51% |
| 5-year return | -85.48% | -45.68% |
| Forward P/E | 10.79 | — |
| EPS (TTM) | $-0.80 | $-0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $213.65M | $44.55M |
| Revenue growth (YoY) | -6.55% | -22.61% |
| Net income (latest FY) | $-38.80M | $-83.78M |
| Gross margin | 56.57% | 58.35% |
| Operating margin | -23.48% | -159.50% |
| Net margin | -18.16% | -188.09% |
| 52-week high | $17.31 | $6.74 |
| 52-week low | $10.56 | $2.93 |
| Distance from 52-week high | -38.94% | -48.63% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +22.99% | +169.65% |
| Average volume | 79.50K | 2.41M |
| Shares outstanding | 42.04M | 125.69M |
| Employees | 80 | 147 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amarin is more profitable, keeping -18.2 cents of every revenue dollar as net income versus -188.1 cents for Aquestive Therapeutics.
- Amarin grew revenue faster in its latest fiscal year (-6.55% vs -22.61%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
AMRN vs AQST FAQ
Which is bigger, Amarin or Aquestive Therapeutics?
Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $434.88M for Aquestive Therapeutics (AQST).
Which stock has performed better over the past year, AMRN or AQST?
AMRN returned -35.47% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Aquestive Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.